+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biodefense Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Biodefense Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Biodefense Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082678
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biodefense Market grew from USD 20.33 billion in 2024 to USD 22.71 billion in 2025. It is expected to continue growing at a CAGR of 11.35%, reaching USD 38.77 billion by 2030.

Biodefense strategies have become indispensable as the convergence of natural outbreaks, synthetic biology and geopolitical tensions intensifies the risk of biological threats. Recent advancements in diagnostic technologies, therapeutics and vaccine platforms have expanded the toolkit available to national and commercial stakeholders. At the same time, regulatory frameworks and public health protocols continue to evolve in response to emerging hazards, requiring agile adaptation across research, manufacturing and deployment channels. This introduction presents a holistic overview of the current biodefense environment, highlighting how evolving threat vectors and technological breakthroughs are reshaping priorities for governments, defense agencies, healthcare providers and private enterprises. By establishing this context, the subsequent analysis will reveal strategic inflection points, segmentation-driven insights and actionable recommendations designed to enhance resilience, optimize resource allocation and maintain strategic advantage in the face of mounting biological challenges.

Transformative Shifts Reshaping the Biodefense Landscape

The biodefense landscape is undergoing transformative shifts driven by dual-use biotechnology, data-driven risk assessment and collaborative governance models. Artificial intelligence has emerged as a cornerstone for predictive modeling and threat analysis systems, while genomic sequencing and genetic engineering accelerate identification of novel pathogens and development of countermeasures. Concurrently, blockchain applications are being deployed to secure sensitive data exchanges and trace the integrity of medical countermeasure supply chains. At the regulatory level, accelerated approval pathways and adaptive licensing frameworks are streamlining clinical development without compromising safety standards. Public-private partnerships have also deepened, forging alliances between defense departments, public health agencies and commercial innovators. This confluence of technological innovation, policy reforms and cooperative deployment is redefining traditional silos, enabling rapid scale-up of testing capacity, targeted distribution of personal protective equipment and agile vaccine development. As the industry pivots toward integrated threat response ecosystems, organizations must realign investments and capabilities to capitalize on emerging paradigms in biodefense.

Cumulative Impact of United States Tariffs 2025 on Biodefense Supply Chains

The introduction of United States tariffs in 2025 has exerted a multifaceted impact on biodefense supply chains and cost structures. Tariff measures applied to imported raw materials and specialized components have increased procurement expenses for diagnostics reagents, high-grade polymers used in protective equipment and active pharmaceutical ingredients. Manufacturers have responded by diversifying sourcing strategies, forging new partnerships with domestic suppliers and accelerating onshore production initiatives. This realignment has alleviated some exposure to international trade disruptions but has also necessitated capital investment to upgrade facilities and re-qualify alternative materials under stringent regulatory standards. In parallel, research and development budgets have absorbed higher input costs, prompting organizations to seek efficiency gains through automation, lean process design and collaborative consortia for shared R&D infrastructure. Vaccine manufacturers, in particular, have restructured contract networks to mitigate tariff impacts on critical fill-finish operations. While these adjustments have bolstered long-term supply resilience, short-term pricing pressures underscore the importance of strategic procurement planning and agile manufacturing frameworks in navigating the evolving tariff environment.

Key Segmentation Insights Across Product, Application, End User, Technology, and Pathogen

Insight derived from a product-type framework indicates that diagnostics-spanning immunoassay-based tests, PCR-based tests and rapid kits-are witnessing both increased demand for high-throughput laboratory platforms and expansion of point-of-care applications. Protective equipment, including coveralls, face shields and respirators, has benefited from material science advancements that enhance breathability and barrier performance while meeting new regulatory requirements. The therapeutics domain, comprising antibacterials, antifungals and antivirals, continues to attract significant R&D investments aimed at broad-spectrum efficacy and reduced time to clinical deployment. Vaccine development technologies focusing on recombinant, subunit and toxoid platforms are diversifying strategic pipelines to address pathogen variation and storage constraints. Application-centered analysis highlights detection methodologies with bulk screening protocols that complement rapid point-of-care systems, prevention strategies anchored by community guidelines and national inoculation programs, research and development activities conducted across preclinical testing and clinical trial phases, and treatment solutions oriented toward emergency response frameworks and therapeutic intervention pathways. End-user segmentation underscores the critical role of commercial sector entities such as pharmaceutical firms and private clinics in early adoption, government and defense bodies including defense departments and public health agencies in large-scale preparedness initiatives, healthcare facilities encompassing clinics and hospitals in routine clinical application, and research institutes-both public research labs and universities-in foundational innovation. Technological segmentation reveals that artificial intelligence applications in predictive modeling and threat analysis systems, biotech advances in genetic engineering and genomic sequencing, blockchain solutions for data security and traceability and nanotechnology breakthroughs in nanocarriers and nanosensors collectively drive platform diversification. Pathogen-focused efforts targeting bacterial agents such as anthrax and plague, biotoxins including botulinum toxin and ricin, fungal threats like candidiasis and cryptococcosis and viral families represented by coronaviruses and influenza strains illustrate the spectrum of defense requirements. Together, this segmentation framework ensures precise resource allocation, informed prioritization of R&D pipelines and tailored deployment strategies to address the complexity of modern biodefense challenges.

Regional Dynamics Driving Biodefense Growth and Collaboration

Regional dynamics exhibit distinct characteristics across the Americas, Europe, Middle East & Africa and Asia-Pacific markets. In the Americas, public-private partnerships and integrated federal programs have accelerated the deployment of diagnostic networks and stockpiling of medical countermeasures, while commercial entities are forging strategic alliances to streamline supply logistics. Europe, Middle East & Africa demonstrates regulatory harmonization initiatives that enable cross-border clinical trial collaboration and coordinated procurement through pan-regional frameworks, with an emphasis on standardizing quality controls and interoperability of data systems. Asia-Pacific markets are prioritizing rapid scale-up of manufacturing capacity and investment in digital surveillance infrastructure, leveraging cloud-based platforms and real-time analytics to detect and contain outbreaks. Each region’s policy environment, investment landscape and ecosystem maturity influences the adoption rate of emerging technologies and underpins tailored approaches to capacity building, workforce training and supply chain resilience.

Leading Companies Driving Innovation in Biodefense Solutions

Industry leaders such as Alnylam Pharmaceuticals, Inc., Altimmune, Inc. and Bavarian Nordic A/S are advancing RNA-based platforms and novel vaccine candidates aimed at rapid response timelines. Professional services firms including BDO USA, LLP provide regulatory compliance, risk assessment and financial advisory support that are critical for navigating complex national and international frameworks. Bharat Biotech Ltd. and the Dynport Vaccine Company by General Dynamics Information Technology have invested heavily in scalable manufacturing infrastructure and contract manufacturing capabilities to meet surge requirements. Elusys Therapeutics, Inc. by Heat Biologics Inc. focuses on monoclonal antibody development for high-priority threats, while Emergent BioSolutions Inc. leverages its proprietary adjuvant technology and fill-finish expertise to enhance global stockpile readiness. Evogen, Inc. and Ichor Medical Systems, Inc. are integrating nanocarrier delivery systems and automated bioprocessing solutions to optimize production efficiency. Pizer Inc. and Serum Institute of India Pvt. Ltd. combine extensive distribution networks with cost-effective vaccine manufacturing, making them key contributors to global immunization campaigns. SIGA Technologies pioneers antiviral therapeutics designed for stockpile resilience, Soligenix, Inc. specializes in novel adjuvant formulations and thermostable vaccine candidates, and Xoma Corporation harnesses antibody discovery platforms for rapid countermeasure development. Collectively, these organizations exemplify diversified strategic approaches, from platform innovation and contract manufacturing to advisory services and supply chain optimization.

Actionable Recommendations for Biodefense Industry Leadership

Industry leaders should prioritize strategic diversification of supply chains by establishing multi-source procurement agreements and reshoring critical manufacturing capabilities while incorporating lean process design and automation to reduce cost volatility. Investment in advanced analytics, artificial intelligence and genomic sequencing platforms will accelerate early threat detection and candidate countermeasure identification, enabling agile adaptation to emerging pathogens. Strengthening public-private partnerships and engaging in cross-sector consortia fosters shared risk mitigation, pooled resource utilization and expedited regulatory alignment. Integration of blockchain solutions enhances data integrity across research, clinical and distribution workflows, improving traceability and reducing compliance overhead. Organizations must also cultivate talent pipelines through specialized training programs and simulation-based drills that test operational readiness under realistic outbreak scenarios. Finally, adopting scenario-based strategic planning-factoring in evolving tariff environments, geopolitical tensions and technological breakthroughs-will ensure resilient, future-proof biodefense postures.

Conclusion: Strengthening Resilience in Biodefense Preparedness

The complexity of the contemporary biodefense landscape demands a holistic, coordinated approach that bridges innovation, regulation and operational readiness. Sustained investment in platform diversification, digital infrastructure and workforce development is essential to maintain strategic flexibility and rapid response capability. Cross-boundary collaboration across governmental, private and academic sectors enhances collective resilience, while adaptive regulatory frameworks ensure safe and efficient deployment of new countermeasures. By leveraging the insights presented here, stakeholders can fortify biodefense ecosystems, anticipate emerging threats and protect public health with scalable, cost-effective solutions.

Market Segmentation & Coverage

This research report categorizes the Biodefense Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Diagnostics
    • Immunoassay-Based Tests
    • PCR-Based Tests
    • Rapid Kits
  • Protective Equipment
    • Coveralls
    • Face Shields
    • Respirators
  • Therapeutics
    • Antibacterials
    • Antifungals
    • Antivirals
  • Vaccines
    • Recombinant Vaccines
    • Subunit Vaccines
    • Toxoid Vaccines
  • Detection
    • Bulk Screening Protocols
    • Point-Of-Care Testing
  • Prevention
    • Community Guidelines
    • Inoculation Programs
  • Research and Development
    • Clinical Trials
    • Preclinical Testing
  • Treatment
    • Emergency Responses
    • Therapeutic Intervention
  • Commercial Sector
    • Pharmaceutical Firms
    • Private Clinics
  • Government and Defense
    • Defense Departments
    • Public Health Agencies
  • Healthcare Facilities
    • Clinics
    • Hospitals
  • Research Institutes
    • Public Research Labs
    • Universities
  • Artificial Intelligence
    • Predictive Modeling
    • Threat Analysis Systems
  • Biotech Advances
    • Genetic Engineering
    • Genomic Sequencing
  • Blockchain Applications
    • Data Security
    • Traceability Solutions
  • Nano-Technology
    • Nanocarriers
    • Nanosensors
  • Bacteria
    • Anthrax
    • Plague
  • Biotoxins
    • Botulinum Toxin
    • Ricin
  • Fungi
    • Candidiasis
    • Cryptococcosis
  • Viruses
    • Coronaviruses
    • Influenza Strains

This research report categorizes the Biodefense Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biodefense Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Alnylam Pharmaceuticals, Inc.
  • Altimmune, Inc.
  • Bavarian Nordic A/S
  • BDO USA, LLP
  • Bharat Biotech Ltd.
  • Dynport Vaccine Company by General Dynamics Information Technology
  • Elusys Therapeutics, Inc. by Heat Biologics Inc.
  • Emergent BioSolutions Inc.
  • Evogen, Inc.
  • Ichor Medical Systems, Inc.
  • Pizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • SIGA Technologies
  • Soligenix, Inc.
  • Xoma Corporation

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biodefense Market, by Product Type
8.1. Introduction
8.2. Diagnostics
8.2.1. Immunoassay-Based Tests
8.2.2. PCR-Based Tests
8.2.3. Rapid Kits
8.3. Protective Equipment
8.3.1. Coveralls
8.3.2. Face Shields
8.3.3. Respirators
8.4. Therapeutics
8.4.1. Antibacterials
8.4.2. Antifungals
8.4.3. Antivirals
8.5. Vaccines
8.5.1. Recombinant Vaccines
8.5.2. Subunit Vaccines
8.5.3. Toxoid Vaccines
9. Biodefense Market, by Application
9.1. Introduction
9.2. Detection
9.2.1. Bulk Screening Protocols
9.2.2. Point-Of-Care Testing
9.3. Prevention
9.3.1. Community Guidelines
9.3.2. Inoculation Programs
9.4. Research and Development
9.4.1. Clinical Trials
9.4.2. Preclinical Testing
9.5. Treatment
9.5.1. Emergency Responses
9.5.2. Therapeutic Intervention
10. Biodefense Market, by End User
10.1. Introduction
10.2. Commercial Sector
10.2.1. Pharmaceutical Firms
10.2.2. Private Clinics
10.3. Government and Defense
10.3.1. Defense Departments
10.3.2. Public Health Agencies
10.4. Healthcare Facilities
10.4.1. Clinics
10.4.2. Hospitals
10.5. Research Institutes
10.5.1. Public Research Labs
10.5.2. Universities
11. Biodefense Market, by Technology
11.1. Introduction
11.2. Artificial Intelligence
11.2.1. Predictive Modeling
11.2.2. Threat Analysis Systems
11.3. Biotech Advances
11.3.1. Genetic Engineering
11.3.2. Genomic Sequencing
11.4. Blockchain Applications
11.4.1. Data Security
11.4.2. Traceability Solutions
11.5. Nano-Technology
11.5.1. Nanocarriers
11.5.2. Nanosensors
12. Biodefense Market, by Pathogen
12.1. Introduction
12.2. Bacteria
12.2.1. Anthrax
12.2.2. Plague
12.3. Biotoxins
12.3.1. Botulinum Toxin
12.3.2. Ricin
12.4. Fungi
12.4.1. Candidiasis
12.4.2. Cryptococcosis
12.5. Viruses
12.5.1. Coronaviruses
12.5.2. Influenza Strains
13. Americas Biodefense Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Biodefense Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Biodefense Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alnylam Pharmaceuticals, Inc.
16.3.2. Altimmune, Inc.
16.3.3. Bavarian Nordic A/S
16.3.4. BDO USA, LLP
16.3.5. Bharat Biotech Ltd.
16.3.6. Dynport Vaccine Company by General Dynamics Information Technology
16.3.7. Elusys Therapeutics, Inc. by Heat Biologics Inc.
16.3.8. Emergent BioSolutions Inc.
16.3.9. Evogen, Inc.
16.3.10. Ichor Medical Systems, Inc.
16.3.11. Pizer Inc.
16.3.12. Serum Institute of India Pvt. Ltd.
16.3.13. SIGA Technologies
16.3.14. Soligenix, Inc.
16.3.15. Xoma Corporation
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BIODEFENSE MARKET MULTI-CURRENCY
FIGURE 2. BIODEFENSE MARKET MULTI-LANGUAGE
FIGURE 3. BIODEFENSE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIODEFENSE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BIODEFENSE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BIODEFENSE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIODEFENSE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIODEFENSE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIODEFENSE MARKET SIZE, BY IMMUNOASSAY-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIODEFENSE MARKET SIZE, BY PCR-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIODEFENSE MARKET SIZE, BY RAPID KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIODEFENSE MARKET SIZE, BY COVERALLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIODEFENSE MARKET SIZE, BY FACE SHIELDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIODEFENSE MARKET SIZE, BY RESPIRATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIODEFENSE MARKET SIZE, BY ANTIBACTERIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIODEFENSE MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIODEFENSE MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIODEFENSE MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIODEFENSE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIODEFENSE MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIODEFENSE MARKET SIZE, BY BULK SCREENING PROTOCOLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIODEFENSE MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIODEFENSE MARKET SIZE, BY PREVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIODEFENSE MARKET SIZE, BY COMMUNITY GUIDELINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIODEFENSE MARKET SIZE, BY INOCULATION PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIODEFENSE MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIODEFENSE MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIODEFENSE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIODEFENSE MARKET SIZE, BY EMERGENCY RESPONSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTIC INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIODEFENSE MARKET SIZE, BY PHARMACEUTICAL FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIODEFENSE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIODEFENSE MARKET SIZE, BY DEFENSE DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIODEFENSE MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIODEFENSE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIODEFENSE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIODEFENSE MARKET SIZE, BY PUBLIC RESEARCH LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIODEFENSE MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIODEFENSE MARKET SIZE, BY PREDICTIVE MODELING, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIODEFENSE MARKET SIZE, BY THREAT ANALYSIS SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIODEFENSE MARKET SIZE, BY GENETIC ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIODEFENSE MARKET SIZE, BY GENOMIC SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIODEFENSE MARKET SIZE, BY DATA SECURITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIODEFENSE MARKET SIZE, BY TRACEABILITY SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BIODEFENSE MARKET SIZE, BY NANOCARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BIODEFENSE MARKET SIZE, BY NANOSENSORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL BIODEFENSE MARKET SIZE, BY BACTERIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL BIODEFENSE MARKET SIZE, BY ANTHRAX, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL BIODEFENSE MARKET SIZE, BY PLAGUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL BIODEFENSE MARKET SIZE, BY BIOTOXINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL BIODEFENSE MARKET SIZE, BY BOTULINUM TOXIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL BIODEFENSE MARKET SIZE, BY RICIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL BIODEFENSE MARKET SIZE, BY FUNGI, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL BIODEFENSE MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL BIODEFENSE MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL BIODEFENSE MARKET SIZE, BY VIRUSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL BIODEFENSE MARKET SIZE, BY CORONAVIRUSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL BIODEFENSE MARKET SIZE, BY INFLUENZA STRAINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 171. CANADA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 172. CANADA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 173. CANADA BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 174. CANADA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 175. CANADA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 176. CANADA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. CANADA BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 178. CANADA BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 179. CANADA BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 180. CANADA BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 181. CANADA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. CANADA BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 183. CANADA BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 184. CANADA BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 185. CANADA BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 186. CANADA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. CANADA BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 188. CANADA BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 189. CANADA BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 190. CANADA BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. CANADA BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 192. CANADA BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 193. CANADA BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 194. CANADA BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 195. CANADA BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 196. MEXICO BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 197. MEXICO BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 198. MEXICO BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 199. MEXICO BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 200. MEXICO BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 201. MEXICO BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. MEXICO BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 203. MEXICO BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 204. MEXICO BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 205. MEXICO BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 206. MEXICO BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. MEXICO BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 208. MEXICO BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 209. MEXICO BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 210. MEXICO BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 211. MEXICO BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 212. MEXICO BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 213. MEXICO BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 214. MEXICO BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 215. MEXICO BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. MEXICO BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 217. MEXICO BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 218. MEXICO BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 219. MEXICO BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 220. MEXICO BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 231. UNITED STATES BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. UNITED STATES BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 233. UNITED STATES BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 234. UNITED STATES BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 235. UNITED STATES BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 236. UNITED STATES BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. UNITED STATES BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 238. UNITED STATES BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 239. UNITED STATES BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 240. UNITED STATES BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. UNITED STATES BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 242. UNITED STATES BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 243. UNITED STATES BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 244. UNITED STATES BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 245. UNITED STATES BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 246. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 257. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 278. AUSTRALIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. AUSTRALIA BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 280. AUSTRALIA BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 281. AUSTRALIA BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 282. AUSTRALIA BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 283. AUSTRALIA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. AUSTRALIA BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 285. AUSTRALIA BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 286. AUSTRALIA BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 287. AUSTRALIA BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 288. AUSTRALIA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 289. AUSTRALIA BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 290. AUSTRALIA BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 291. AUSTRALIA BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 292. AUSTRALIA BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 293. AUSTRALIA BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 298. CHINA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 299. CHINA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 300. CHINA BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 301. CHINA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 302. CHINA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 303. CHINA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 304. CHINA BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 305. CHINA BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 306. CHINA BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 307. CHINA BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 308. CHINA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. CHINA BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 310. CHINA BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 311. CHINA BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 312. CHINA BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 313. CHINA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 314. CHINA BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 315. CHINA BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 316. CHINA BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 317. CHINA BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 318. CHINA BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 319. CHINA BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 320. CHINA BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 321. CHINA BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 322. CHINA BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 323. INDIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 324. INDIA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 325. INDIA BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 326. INDIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 327. INDIA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 328. INDIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 329. INDIA BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 330. INDIA BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 331. INDIA BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 332. INDIA BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 333. INDIA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 334. INDIA BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 335. INDIA BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 336. INDIA BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 337. INDIA BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 338. INDIA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 339. INDIA BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 340. INDIA BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 341. INDIA BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 342. INDIA BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 343. INDIA BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 344. INDIA BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 345. INDIA BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 346. INDIA BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 347. INDIA BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 348. INDONESIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 349. INDONESIA BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 350. INDONESIA BIODEFENSE MARKET SIZE, BY PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 351. INDONESIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 352. INDONESIA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 353. INDONESIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 354. INDONESIA BIODEFENSE MARKET SIZE, BY DETECTION, 2018-2030 (USD MILLION)
TABLE 355. INDONESIA BIODEFENSE MARKET SIZE, BY PREVENTION, 2018-2030 (USD MILLION)
TABLE 356. INDONESIA BIODEFENSE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 357. INDONESIA BIODEFENSE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 358. INDONESIA BIODEFENSE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 359. INDONESIA BIODEFENSE MARKET SIZE, BY COMMERCIAL SECTOR, 2018-2030 (USD MILLION)
TABLE 360. INDONESIA BIODEFENSE MARKET SIZE, BY GOVERNMENT AND DEFENSE, 2018-2030 (USD MILLION)
TABLE 361. INDONESIA BIODEFENSE MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2030 (USD MILLION)
TABLE 362. INDONESIA BIODEFENSE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 363. INDONESIA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 364. INDONESIA BIODEFENSE MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2030 (USD MILLION)
TABLE 365. INDONESIA BIODEFENSE MARKET SIZE, BY BIOTECH ADVANCES, 2018-2030 (USD MILLION)
TABLE 366. INDONESIA BIODEFENSE MARKET SIZE, BY BLOCKCHAIN APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 367. INDONESIA BIODEFENSE MARKET SIZE, BY NANO-TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 368. INDONESIA BIODEFENSE MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 369. INDONESIA BIODEFENSE MARKET SIZE, BY BACTERIA, 2018-2030 (USD MILLION)
TABLE 370. INDONESIA BIODEFENSE MARKET SIZE, BY BIOTOXINS, 2018-2030 (USD MILLION)
TABLE 371. INDONESIA BIODEFENSE MARKET SIZE, BY FUNGI, 2018-2030 (USD MILLION)
TABLE 372. INDONESIA BIODEFENSE MARKET SIZE, BY VIRUSES, 2018-2030 (USD MILLION)
TABLE 373. JAPAN BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 374. JAPAN BIODEFENSE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 375. JAPAN BIODEFEN

Companies Mentioned

  • Alnylam Pharmaceuticals, Inc.
  • Altimmune, Inc.
  • Bavarian Nordic A/S
  • BDO USA, LLP
  • Bharat Biotech Ltd.
  • Dynport Vaccine Company by General Dynamics Information Technology
  • Elusys Therapeutics, Inc. by Heat Biologics Inc.
  • Emergent BioSolutions Inc.
  • Evogen, Inc.
  • Ichor Medical Systems, Inc.
  • Pizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • SIGA Technologies
  • Soligenix, Inc.
  • Xoma Corporation

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biodefense Market by Product, End-User - Global Forecast 2025-2030 - Product Image

Biodefense Market by Product, End-User - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Biodefense Market Report 2025 - Product Image

Biodefense Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Biodefense - Global Strategic Business Report - Product Image

Biodefense - Global Strategic Business Report

  • Report
  • 363 Pages
  • Global
From
Biodefense - A Global Market Overview - Product Image

Biodefense - A Global Market Overview

  • Report
  • 255 Pages
  • Global
From
Bio-Detection - Global Strategic Business Report - Product Image

Bio-Detection - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.